title: Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma.
abstract: BACKGROUND
  Systemic treatment of metastatic renal cell carcinoma (mRCC) with targeted therapies became widely accepted; however, there are few patients who greatly benefit from immunochemotherapy (ICT). It is crucial to recognize these patients for individual treatment.
  
  
  OBJECTIVE
  Definition of protein patterns in tissue and serum from mRCC-patients to predict benefit from ICT.
  
  
  METHODS
  Twenty-five tissue samples and 59 sera were analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Protein peaks of interest were identified by 2D-PAGE and peptide mass fingerprinting. Validation was carried out by Western Blot and ELISA.
  
  
  RESULTS
  Protein patterns associated with therapy response were determined. Caveolin-1 (CAV-1) and plasminogen activator inhibitor 1 (PAI-1) were identified in tissue; serum amyloid A (SAA) and transthyretin (TTR) were found in serum.
  
  
  CONCLUSIONS
  Individual prediction of therapy benefit and selecting patients for ICT based on molecular biological profiles appear to be feasible in the future.
authors.affiliation: Department of Urology, University Hospitals Jena, Lessingstraße 1, 07743 Jena, Germany. martina.walter@med.uni-jena.de
authors.forename: Martina
authors.initials: M
authors.lastname: Walter
authors.forename: Christian
authors.initials: C
authors.lastname: Heinze
authors.forename: Thomas
authors.initials: T
authors.lastname: Steiner
authors.forename: Rico
authors.initials: R
authors.lastname: Pilchowski
authors.forename: Ferdinand
authors.initials: F
authors.lastname: von Eggeling
authors.forename: Heiko
authors.initials: H
authors.lastname: Wunderlich
authors.forename: Kerstin
authors.initials: K
authors.lastname: Junker
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D051242:Caveolin 1 / Q000032:analysis*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000097:blood* / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000097:blood / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011228:Prealbumin / Q000032:analysis* / Q000378:metabolism; D011379:Prognosis; D040081:Protein Array Analysis; D012074:Remission Induction / Q000379:methods; D000685:Serum Amyloid A Protein / Q000032:analysis* / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D051242:Caveolin 1; D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; D011228:Prealbumin; D000685:Serum Amyloid A Protein